- Home
- LGND vs ARWR Comparison
LGND vs ARWR Comparison
Compare LGND & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- ARWR
- Stock Information
- Founded
- LGND 1987
- ARWR 2003
- Country
- LGND United States
- ARWR United States
- Employees
- LGND N/A
- ARWR N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- LGND Health Care
- ARWR Health Care
- Exchange
- LGND Nasdaq
- ARWR Nasdaq
- Market Cap
- LGND 2.2B
- ARWR 2.6B
- IPO Year
- LGND 1992
- ARWR 1993
- Fundamental
- Price
- LGND $120.67
- ARWR $19.90
- Analyst Decision
- LGND Strong Buy
- ARWR Buy
- Analyst Count
- LGND 6
- ARWR 11
- Target Price
- LGND $145.00
- ARWR $43.33
- AVG Volume (30 Days)
- LGND 79.6K
- ARWR 2.5M
- Earning Date
- LGND 02-27-2025
- ARWR 02-10-2025
- Dividend Yield
- LGND N/A
- ARWR N/A
- EPS Growth
- LGND 160.46
- ARWR N/A
- EPS
- LGND 2.47
- ARWR N/A
- Revenue
- LGND $152,422,000.00
- ARWR $2,500,000.00
- Revenue This Year
- LGND $26.86
- ARWR $3,336.78
- Revenue Next Year
- LGND $14.95
- ARWR $124.29
- P/E Ratio
- LGND $48.82
- ARWR N/A
- Revenue Growth
- LGND N/A
- ARWR N/A
- 52 Week Low
- LGND $67.72
- ARWR $17.05
- 52 Week High
- LGND $129.90
- ARWR $36.72
- Technical
- Relative Strength Index (RSI)
- LGND 59.36
- ARWR 49.40
- Support Level
- LGND $110.42
- ARWR $17.57
- Resistance Level
- LGND $119.26
- ARWR $21.84
- Average True Range (ATR)
- LGND 3.82
- ARWR 1.06
- MACD
- LGND 0.61
- ARWR 0.11
- Stochastic Oscillator
- LGND 81.35
- ARWR 54.57
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.